Agreed, the timing is what caught my attention. If by chance BIPH is the reverse merger for the Nugenerex spin out, it could be huge for current BIPH shareholders. They are partnered with Merck's Keytruda for immunotherapy clinical trials and a number of other things in the pipeline. And the CEOs of BIPH and GNBT are both named "Joe", so it must be! LOL, this board needs some excitement.
News 
Market Data 
Discover 
